In Vitro Diagnostics (IVD) Quality Control Market Report

• Siemens Healthineers AG (Germany) achieved a sustainability milestone by becoming the first IVD manufacturer to earn the My Green Lab ACT Ecolabel for both its Atellica analyzers and over 150 reagents. This certification provides transparent environmental impact data, evaluating factors like energy use and waste. (July 07, 2025)
• Randox Laboratories Ltd. (UK) and Mindray (China) partnered to enhance quality assurance within the IVD market. Mindray had actively participated in Randox’s RIQAS external quality assessment (EQA) programmes, including those for immunoassay, serology, HbA1c, and clinical chemistry, achieving excellent performance. This longstanding partnership also led Randox to include specific values for Mindray series instruments within their Acusera quality control portfolio. This collaboration provided laboratories using Mindray systems with validated third-party controls, thereby enabling them to ensure the accuracy and reliability of their testing procedures. (June 21, 2024).

Drivers: Regulatory Mandates and Diagnostic Complexity Drive IVD QC Growth

Stringent regulatory requirements and accreditation standards (e.g., CLIA, ISO 15189) mandating rigorous quality control procedures are primary drivers. The increasing volume and complexity of IVD testing, coupled with the adoption of sophisticated new assays, necessitate comprehensive QC measures to ensure accuracy and reliability. Growing healthcare expenditure globally supports investment in quality assurance. Rising disease prevalence increases the total number of tests performed, amplifying the need for QC. Furthermore, the increasing focus on patient safety and reducing diagnostic errors drives laboratories to implement robust QC programs.

Opportunities: Market Expansion Through Innovation and Emerging Markets

Significant opportunities lie in developing automated and integrated QC solutions that streamline workflows and reduce manual effort. Expansion into emerging markets with developing healthcare infrastructure presents substantial growth potential. Growth in Point-of-Care Testing (POCT) creates demand for suitable, user-friendly QC products at the point of care. The increasing adoption of laboratory automation drives demand for corresponding QC systems. Development of IQC (Internal Quality Control) and EQA (External Quality Assessment) solutions tailored for specific regions and instrument types offers new avenues. Furthermore, offering value-added services like maintenance, training, and consulting related to QC implementation presents lucrative opportunities.

Challenges: Addressing Cost, Complexity, and Compliance

Key challenges include the high cost associated with comprehensive QC programs, including advanced automated systems and specialized controls, limiting adoption in resource-constrained settings. The complexity of managing QC for a vast range of assays and instrument platforms poses operational difficulties. Navigating diverse and evolving regulatory requirements globally is a significant hurdle. The market demands skilled laboratory personnel trained in implementing, monitoring, and interpreting QC results correctly. Ensuring the availability and appropriate use of QC materials, alongside the pressure to reduce costs while maintaining quality, presents ongoing strategic challenges for market players.

The global IVD Quality Control market, focused on ensuring the accuracy and reliability of in vitro diagnostic tests, is experiencing steady growth driven by the critical need for quality assurance across the expanding diagnostics landscape. The market is valued at approximately USD 1.60 billion in 2024 and is projected to reach around USD 2.16 billion by 2030, growing at a Compound Annual Growth Rate (CAGR) of approximately 5% during the forecast period. Key drivers include stringent regulatory requirements mandating QC procedures, the increasing volume and complexity of IVD testing globally, and the rising prevalence of chronic diseases necessitating frequent monitoring. Furthermore, the adoption of advanced IVD instruments requiring specific QC validation, growing healthcare expenditure, and increasing emphasis on patient safety and reducing diagnostic errors are fuelling market expansion. Technological advancements, such as automated QC systems, integrated solutions, and intelligent QC algorithms for real-time monitoring, alongside the continued essential use of traditional liquid and lyophilized control materials, are enhancing the efficiency and effectiveness of quality control processes in laboratories worldwide.